Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Rapt Therapeutics (RAPT) had Income from Continuous Operations of $-17.58M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-17.58M |
|
-- |
|
-- |
|
$19.37M |
|
$-19.37M |
|
$1.79M |
|
$-17.58M |
|
$-17.58M |
|
$-17.58M |
|
|
Income from Continuous Operations |
$-17.58M |
$-17.58M |
|
$-17.58M |
|
$-19.37M |
|
$-19.90M |
|
26.96M |
|
26.96M |
|
$-0.65 |
|
$-0.65 |
|
| Balance Sheet Financials | |
$161.04M |
|
$0.77M |
|
$4.69M |
|
$165.74M |
|
$13.38M |
|
-- |
|
$0.39M |
|
$13.76M |
|
$151.98M |
|
$151.98M |
|
$151.98M |
|
16.86M |
|
| Cash Flow Statement Financials | |
$-76.14M |
|
$-55.86M |
|
$0.20M |
|
$169.74M |
|
$37.93M |
|
$-131.81M |
|
$14.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-76.23M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.57% |
|
-11.57% |
|
-10.61% |
|
-11.57% |
|
$9.02 |
|
$-2.83 |
|
$-2.82 |
|